Guanze Medical Information Industry (Holding) Co., Ltd. (Guanze Medical, 02427) announced that a preliminary review of its unaudited consolidated management accounts for the twelve months ended 31 December 2025 indicates a net loss attributable to owners of approximately RMB28.00 million–RMB30.00 million, versus a net profit of about RMB17.20 million for the prior year.

The swing into loss is primarily driven by three factors:

1. Lower average selling price and reduced shipment volume of imaging film products during 2025.

2. Revenue contraction to roughly RMB88.40 million, down 43.22% from RMB155.70 million in 2024.

3. A potential impairment of property, plant and equipment recognised in 2025.

The Board emphasised that the figures are based on internal management accounts and may change after auditor review. The audited results are scheduled for release by end-March 2026.

The announcement also reiterates that the company is currently the subject of a mandatory unconditional cash offer by FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED, first disclosed on 11 and 20 February 2026. Because the profit warning constitutes a profit forecast under the Hong Kong Code on Takeovers and Mergers, it has not yet been reported on by financial advisers or auditors as required under Rule 10.4 of the Takeovers Code.

Guanze Medical advises shareholders and potential investors to exercise caution when dealing in the company’s securities until the audited financial statements are available.